DXSP DXS International Plc

 
TIDMDXSP 
 

DXS INTERNATIONAL PLC

Holding in Company and Total Voting Rights

The Board of DXS International plc (the "Company"), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems has received notification under the DTR that following the Placing announced on 17 May 2023, the following persons have voting rights in the Company as follows:

 
3. Details of person subject to the notification obligation (iv) 
Name                                 Foresight Group LLP 
City and country of registered 
 office (if applicable)              London, UK 
4. Full name of shareholder(s) (if different from 3.) (v) 
--------------------------------------------------------------------------------------------- 
Name                                 Thames Ventures VCT 1 plc 
-----------------------------------  -------------------------------------------------------- 
City and country of registered 
 office (if applicable)              London, UK 
-----------------------------------  -------------------------------------------------------- 
5. Date on which the threshold 
 was crossed or reached (vi) :       24.05.23 
-----------------------------------  -------------------------------------------------------- 
6. Date on which issuer notified 
 (DD/MM/YYYY):                       24.05.23 
-----------------------------------  -------------------------------------------------------- 
7. Total positions of person(s) subject to the notification obligation 
--------------------------------------------------------------------------------------------- 
                                                                              Total number 
                                     % of voting rights                      of voting rights 
                % of voting rights   through financial                        held in issuer 
                 attached to shares  instruments (total    Total of both       (8.A + 8.B) 
                  (total of 8. A)    of 8.B 1 + 8.B 2)    in % (8.A + 8.B)        (vii) 
--------------  -------------------  ------------------  -----------------  ----------------- 
Resulting 
 situation 
 on the date 
 on which 
 threshold 
 was crossed 
 or reached                   11.71               11.71                             7,500,000 
--------------  -------------------  ------------------  -----------------  ----------------- 
Position        n/a                  n/a                 n/a 
 of previous 
 notification 
 (if 
 applicable) 
--------------  -------------------  ------------------  -----------------  ----------------- 
 
 
 
 8. Notified details of the resulting situation on the date on 
 which the threshold was crossed or reached (viii) 
---------------------------------------------------------------------------- 
A: Voting rights attached to shares 
---------------------------------------------------------------------------- 
Class/type 
 of 
 shares 
 ISIN code 
 (if possible)       Number of voting rights (ix)   % of voting rights 
------------------ 
                        Direct         Indirect       Direct      Indirect 
                       (DTR5.1)       (DTR5.2.1)     (DTR5.1)    (DTR5.2.1) 
------------------  --------------  --------------  ----------  ------------ 
GB00B2Q6HZ92             7,500,000             n/a       11.71           n/a 
------------------  --------------  --------------  ----------  ------------ 
 
 
SUBTOTAL 
 8. A                                    7,500,000                     11.71 
------------------  ------------------------------  ------------------------ 
 

In accordance with the FCA's Disclosure Guidance and Transparency Rules, as at 24 May 2023 the Company's issued share capital consists of 64,022,124 Ordinary Shares of 0.33pence each, each with one voting right. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company is 64,022,124.

The above figure of 64,022,124 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

The Directors of DXS International plc accept responsibility for this announcement

Enquiries:

 
David Immelman (Chief Executive)            01252 719800 
 DXS International plc             david@dxs-systems.com 
Wrecclesham House 
 Wrecclesham Road 
 Farnham 
 Surrey 
 GU10 4PS 
www.dxs-systems.co.uk 
 
 
Corporate Advisor 
David Papworth 
 City & Merchant    0207 101 7676 
 
 
Corporate Broker 
Hybridan LLP 
 Claire Louise Noyce   020 3764 2341 
 

Note to Editors:

DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively which should significantly contribute towards the NHS achieving its projected efficiency savings.

(END) Dow Jones Newswires

May 25, 2023 02:00 ET (06:00 GMT)

DXS (AQSE:DXSP)
Historical Stock Chart
From Jan 2025 to Feb 2025

DXS (AQSE:DXSP)
Historical Stock Chart
From Feb 2024 to Feb 2025